Ys Biopharma Co Stock Price Prediction
| YS Stock | 0.56 0.02 3.70% |
YS Biopharma stock price prediction is an act of determining the future value of YS Biopharma shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of YS Biopharma's future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of YS Biopharma and does not consider all of the tangible or intangible factors available from YS Biopharma's fundamental data. We analyze noise-free headlines and recent hype associated with YS Biopharma Co, which may create opportunities for some arbitrage if properly timed. Below are the key fundamental drivers impacting YS Biopharma's stock price prediction:
EPS Estimate Next Year (0.33) | Wall Street Target Price 5.1 | Quarterly Revenue Growth (0.14) |
It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of YS Biopharma based on different types of headlines from major news networks to social media. The YS Biopharma stock price prediction module provides an analysis of price elasticity to changes in media outlook on YS Biopharma over a specific investment horizon. Using YS Biopharma hype-based prediction, you can estimate the value of YS Biopharma Co from the perspective of YS Biopharma response to recently generated media hype and the effects of current headlines on its competitors.
This module is based on analyzing investor sentiment around taking a position in YS Biopharma. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in YS Biopharma to buy its stock at a price that has no basis in reality. In that case, they are not buying YS Biopharma because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
YS Biopharma after-hype prediction price | USD 0.5 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
YS Biopharma |
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of YS Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of YS Biopharma in the context of predictive analytics.
YS Biopharma After-Hype Price Prediction Density Analysis
As far as predicting the price of YS Biopharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in YS Biopharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of YS Biopharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
YS Biopharma Estimiated After-Hype Price Volatility
In the context of predicting YS Biopharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on YS Biopharma's historical news coverage. YS Biopharma's after-hype downside and upside margins for the prediction period are 0.03 and 6.00, respectively. We have considered YS Biopharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
YS Biopharma is dangerous asset. Analysis and calculation of next after-hype price of YS Biopharma is based on 3 months time horizon.
YS Biopharma Stock Price Prediction Analysis
Have you ever been surprised when a price of a company such as YS Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading YS Biopharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with YS Biopharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
| 1.00 | 5.50 | 0.04 | 0.20 | 2 Events / Month | 1 Events / Month | In a few days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
| 0.56 | 0.50 | 7.41 |
|
YS Biopharma Hype Timeline
As of December 6, 2023 YS Biopharma is listed for 0.56. The entity has historical hype elasticity of -0.04 and average elasticity to hype of competition of -0.2. YS Biopharma is projected to decline in value after the next headline with the price expected to drop to 0.5. The average volatility of media hype impact on the company price is over 100%. The price decline on the next newsis expected to be -7.41% whereas the daily expected return is at this time at -1.0%. The volatility of related hype on YS Biopharma is about 2784.81% with expected price after next announcement by competition of 0.36. About 14.0% of the company outstanding shares are owned by institutional investors. The company recorded a loss per share of 0.29. YS Biopharma had not issued any dividends in recent years. Allowing for the 90-day total investment horizon the next projected press release will be in a few days. Check out YS Biopharma Basic Forecasting Models to cross-verify your projections.YS Biopharma Related Hype Analysis
Having access to credible news sources related to YS Biopharma's direct competition is more important than ever and may enhance your ability to predict YS Biopharma's future price movements. Getting to know how YS Biopharma rivals react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how YS Biopharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| AXTA | Axalta Coating Systems | 0.24 | 8 per month | 1.40 | 0.11 | 2.44 | (2.88) | 9.10 | |
| PKIN | Pekin Life Insurance | 0.00 | 0 per month | 0.00 | (0.0203) | 0.00 | 0.00 | 2.59 | |
| TIPGF | Titan Petrochemicals Group | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| AVNT | Avient Corp | (0.16) | 7 per month | 0.00 | (0.1) | 3.38 | (3.11) | 11.03 | |
| MOS | The Mosaic | (1.61) | 6 per month | 0.00 | (0.07) | 4.09 | (3.53) | 11.68 | |
| SLF | Sun Life Financial | (0.46) | 5 per month | 1.06 | 0.07 | 1.97 | (1.96) | 5.20 | |
| BCPC | Balchem | (0.23) | 5 per month | 0.00 | (0.08) | 1.89 | (2.43) | 7.56 | |
| TRUP | Trupanion | 0.64 | 5 per month | 4.24 | 0.0083 | 11.28 | (6.61) | 24.78 |
YS Biopharma Additional Predictive Modules
Most predictive techniques to examine YS Biopharma price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for YS Biopharma using various technical indicators. When you analyze YS Biopharma charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About YS Biopharma Predictive Indicators
The successful prediction of YS Biopharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as YS Biopharma Co, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of YS Biopharma based on analysis of YS Biopharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to YS Biopharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to YS Biopharma's related companies. Story Coverage note for YS Biopharma
The number of cover stories for YS Biopharma depends on current market conditions and YS Biopharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that YS Biopharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about YS Biopharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
YS Biopharma Short Properties
YS Biopharma's future price predictability will typically decrease when YS Biopharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of YS Biopharma Co often depends not only on the future outlook of the potential YS Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. YS Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 93.1 M | |
| Cash And Short Term Investments | 370.1 M |
Check out YS Biopharma Basic Forecasting Models to cross-verify your projections. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for YS Biopharma Stock analysis
When running YS Biopharma's price analysis, check to measure YS Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy YS Biopharma is operating at the current time. Most of YS Biopharma's value examination focuses on studying past and present price action to predict the probability of YS Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move YS Biopharma's price. Additionally, you may evaluate how the addition of YS Biopharma to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
Is YS Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of YS Biopharma. If investors know YS Biopharma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about YS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.29) | Revenue Per Share 6.524 | Quarterly Revenue Growth (0.14) | Return On Equity (0.45) |
The market value of YS Biopharma is measured differently than its book value, which is the value of YS Biopharma that is recorded on the company's balance sheet. Investors also form their own opinion of YS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is YS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because YS Biopharma's market value can be influenced by many factors that don't directly affect YS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between YS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if YS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, YS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.